{
    "Trade/Device Name(s)": [
        "Atellica\u00ae CH High Sensitivity C-Reactive Protein 2 (hCRP2)"
    ],
    "Submitter Information": "Siemens HealthCare Diagnostics Inc.",
    "510(k) Number": "K233242",
    "Predicate Device Reference 510(k) Number(s)": [
        "K212559"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQD"
    ],
    "Summary Letter Date": "January 18, 2024",
    "Summary Letter Received Date": "October 20, 2023",
    "Submission Date": "October 20, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-Reactive Protein Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "C-Reactive Protein (CRP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium heparin)",
        "Plasma (Sodium heparin)",
        "Plasma (K2 EDTA)"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "Sodium heparin tube",
        "K2 EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae CH Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Particle enhanced immunonephelometry"
    ],
    "Methodologies": [
        "Immunonephelometric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) immunonephelometric assay for quantitative CRP measurement in serum and plasma",
    "Indications for Use Summary": "For in vitro quantitative determination of C-Reactive Protein (CRP) concentration in human serum and plasma on the Atellica CH Analyzer; used to aid identification of individuals at risk for future cardiovascular disease and as an independent marker of prognosis for recurrent events in patients with stable coronary disease or acute coronary syndromes.",
    "fda_folder": "Immunology"
}